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RESEARCH ARTICLE
Glypican-3 Targeting of Liver Cancer Cells Using
Multifunctional Nanoparticles
James O. Park, Zachary Stephen, Conroy Sun, Omid Veiseh, Forrest M. Kievit, Chen Fang, Matthew Leung,
Hyejung Mok, and Miqin Zhang
Abstract
Imaging is essential in accurately detecting, staging, and treating primary liver cancer (hepatocellular carcinoma [HCC]), one of the
most prevalent and lethal malignancies. We developed a novel multifunctional nanoparticle (NP) specifically targeting glypican-3
(GPC3), a proteoglycan implicated in promotion of cell growth that is overexpressed in most HCCs. Quantitative real-time
polymerase chain reaction was performed to confirm the differential GPC3 expression in two human HCC cells, Hep G2 (high) and
HLF (negligible). These cells were treated with biotin-conjugated GPC3 monoclonal antibody (aGPC3) and subsequently targeted
using superparamagnetic iron oxide NPs conjugated to streptavidin and Alexa Fluor 647. Flow cytometry demonstrated that only
GPC3-expressing Hep G2 cells were specifically targeted using this aGPC3-NP conjugate (fourfold mean fluorescence over
nontargeted NP), and magnetic resonance imaging (MRI) experiments showed similar findings (threefold R2 relaxivity). Confocal
fluorescence microscopy localized the aGPC3 NPs only to the cell surface of GPC3-expressing Hep G2 cells. Further characterization
of this construct demonstrated a negatively charged, monodisperse, 50 nm NP, ideally suited for tumor targeting. This GPC3-specific
NP system, with dual-modality imaging capability, may enhance pretreatment MRI, enable refined intraoperative HCC visualization
by near-infrared fluorescence, and be potentially used as a carrier for delivery of tumor-targeted therapies, improving patient
outcomes.
W ITH OVER 660,000 NEW CASES and 630,000resultant deaths estimated in 2009, primary liver
cancer, or hepatocellular carcinoma (HCC), is the fifth
most prevalent malignancy and the third leading cause of
cancer-related deaths worldwide.1–3 Although 80% of cases
occur in regions where hepatitis B infection is endemic, the
incidence of HCC in the United States is rising at epidemic
proportions as a result of the rampant spread of hepatitis C
in the 1950s and 1960s.2–4 HCC is a highly lethal disease, as
demonstrated by the equal annual incidence and mortality,
and the dismal 8-month median survival without treat-
ment5 is improved only by a modest 3 months when the
best chemotherapy available, sorafenib, is employed.6 On
the contrary, when HCC is detected at an early stage,
curative treatments such as surgical resection, liver
transplantation, and ablative therapies can be used,
achieving 5-year survival rates of up to 75%, highlighting
the importance of early detection.7–9
Diagnosis of early-stage HCC is heavily reliant on quality
multiphase, contrast-enhanced computed tomography
(CT) and magnetic resonance imaging (MRI), current gold
standards.10 Although characteristic arterial enhancement
with portal venous washout of a liver lesion on CT or MRI is
diagnostic for HCC, indeterminate lesions are frequently
detected,10,11 prompting costly repeat imaging or biopsies
with bleeding or tumor-seeding risks,12,13 all resulting in
delay of diagnosis and treatment. Furthermore, eligibility
for surgical resection or liver transplantation based on
suboptimal scans leads to early recurrences and poor
outcomes or missed treatment opportunities.
Several nanoparticle (NP) systems are being investi-
gated for use in cancer diagnostics and therapeutics.14–17
HCC targeting with NPs remains challenging as Kupffer
cells, specialized macrophages dispersed throughout liver
sinusoids that comprise an elaborate reticuloendothelial
system (RES), take up these particles and interfere with the
imaging or delivery of therapeutic payloads.17–19 Much
effort has been devoted to optimizing selective delivery of
NPs to tumors while evading the RES, using surface
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modification of NPs with antifouling polymers such as
polyethylene glycol (PEG) and various tissue-specific
ligands.20,21 Strategies that identify HCC-specific cell
surface moieties to conjugate to achieve superior specifi-
city hold the most promise. Vascular endothelial growth
factor, epidermal growth factor receptor, aptamers, and
small molecules such as galactose have been reported as
potential targeting moieties for specific delivery of NPs
and drugs to HCC cells.22–25 However, the demand for
novel targeting ligands for HCC-specific delivery remains
high as no single receptor is uniformly expressed by the
heterogeneous population of HCCs, and the efficiency of
existing HCC-targeting ligands is less than ideal.
Furthermore, a two-step pretargeting approach to further
enhance the signal for antibody-targeted imaging and
treatment has been reported.26,27
Glypican-3 (GPC3) was selected as a novel molecular
target in this study for HCC based on qualities crucial to
successful targeting and promising for future applications.
GPC3 is a heparan sulfate proteoglycan essential in
regulating embryonal cell growth, as evidenced by its
mutation causing the Simpson-Golabi-Behmel overgrowth
syndrome.28 Although its expression is absent in normal
adult tissues, GPC3 is significantly overexpressed in up to
80% of human HCCs.29–31 Attached to the cell membrane
via a glycosyl-phosphatidylinositol anchor, GPC3 is readily
accessible for antibody-mediated targeting and bind-
ing.29,32 Moreover, GPC3 has been shown to promote
HCC growth by stimulating the canonical Wnt signaling
pathway, exhibiting potential as an important therapeutic
target.32,33 These auspicious attributes make GPC3 an ideal
biomarker for HCC targeting.
We developed a novel dual-modality imaging NP
system designed to specifically target liver cancer cells
expressing GPC3. For dual near-infrared fluorescence
(NIRF) and MRI, a near-infrared (NIR) fluorophore,
Alexa Fluor 647, was covalently conjugated to iron oxide
NPs. Biotinylated monoclonal antibody against GPC3
(aGPC3) used to pretarget GPC3-expressing HCC cells
was subsequently targeted using NP via noncovalent
streptavidin–biotin interaction. The size, surface charge,
and morphology of resulting aGPC3 NPs were character-
ized by dynamic light scattering and transmission electron
microscopy (TEM), respectively. Differential intracellular
expression level of GPC3 was quantitatively analyzed by
real-time polymerase chain reaction (PCR) for human
HCC cells, Hep G2 (high in GPC3) and HLF (low in
GPC3). Targeted delivery of aGPC3 NPs to GPC3-
expressing Hep G2 cells was examined quantitatively by
flow cytometry and MRI. The enhanced intracellular
extent of NIR fluorophore by specific uptake of aGPC3
NPs in GPC3-expressing HCC cells was visualized using
confocal fluorescence imaging.
Materials and Methods
Preparation of Iron Oxide NPs and Surface
Modification
Iron oxide NPs were prepared as previously described.34
Oleic acid–coated NPs synthesized by thermal decomposi-
tion of iron oleate complex were reacted with triethoxy-
silylpropylsuccinic anhydride (SAS, Gelest, Morrisville,
PA) using ligand exchange and condensation to form
hydrophilic SAS-coated NPs. Amine-functionalized PEG
was attached via N,N-dicyclohexylcarbodiimide (DCC)-
mediated coupling. The NP concentration was adjusted to
4 mg/mL in 150 mM boric acid, pH 8.0. Succinimidyl-
iodoacetate (SIA) (4 mg; Invitrogen, Carlsbad, CA)
dissolved in 100 mL dimethyl sulfoxide (DMSO) was
added to 1 mL NP solution in an amber glass vial and
reacted at room temperature (RT) overnight on a rotator.
A Sephracyl-200 column (GE Healthcare, Piscataway, NJ)
was eluted with 25 mL 150 mM boric acid, pH 8.0, and the
iodoacetate functionalized NPs were purified using the
column. Streptavidin (AV) (5 mg, lyophilized in 10 mM
phosphate-buffered saline [PBS], pH 7.4; Invitrogen) was
dissolved in 1 mL deionized water. Alexa Fluor 647 (0.5 mg;
Invitrogen) was dissolved in 100 mL DMSO, and 50 mL
was added to the AV. The reaction was covered in foil and
placed on a shaker for 1 hour at RT. A PD-10 desalting
column (GE Healthcare) was eluted with 25 mL 50 mM
Na bicarbonate, pH 8.5, and the fluorophore-labeled
AV was purified. Sixty microliters of N-succinimidyl-S-
acetylthioacetate (SATA; Invitrogen) dissolved in DMSO
at 1 mg/mL was added to the purified fluorophore-
(Alexa Fluor 647) labeled AV (AV-allophycocyanin
[APC]) and reacted on a shaker for 2 hours at RT. To a
1 mg aliquot of purified AV-APC, 55 mL of deprotection
solution (0.5 M hydroxylamine, 25 mM ethylenediami-
netetraacetic acid [EDTA], pH 7.2) was added, reacted for
40 minutes, and then Zeba spin column purified. The NP-
SIA concentration was adjusted to 2 mg/mL and then
added to the purified AV-APC in an amber vial and
reacted overnight on a shaker at RT. The AV-APC-labeled
NP (NP-AV-APC) was purified with a Sephracyl-200 col-
umn. The Fe concentration was determined by inductively
coupled plasma atomic emission spectroscopy (Thermo
Jarrell Ash Corporation, Franklin, MA). Figure 1A illus-
trates the synthesis of NP-AV-APC.
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NP Characterization and TEM
The fluorescence spectra of NP, AV-APC, and NP-AV-APC
were measured with an excitation wavelength of 600 nm
using the SpectraMax M2 microplate reader (Molecular
Devices, Sunnyvale, CA). The surface charge and hydro-
dynamic size of the NPs were measured in PBS using a
Zetasizer Nanoseries dynamic light-scattering particle size
analyzer (Malvern, Worcestershire, UK). The aGPC3 NPs
were loaded onto a grid and then dried in a desiccator at RT
for TEM analysis. TEM samples were observed on a Phillips
CM100 TEM (Phillips, Eindhoven, The Netherlands) operat-
ing at 100 kV with a Gatan 689 (Gatan Inc., Pleasanton, CA)
digital slow scan camera.
Cell Culture
Human HCC cell lines, Hep G2 (American Type Culture
Collection, Manassas, VA) and HLF (Japanese Collection of
Research Bioresources, Shinjuku, Japan), were maintained in
Eagle’s Minimum Essential Medium (MEM) and Dulbecco’s
Modified Essential Medium (DMEM), respectively, supple-
mented with 10% (v/v) fetal bovine serum (FBS; Atlanta
Biologicals, Lawrenceville, GA) and 100 U/mL penicillin-
streptomycin (Invitrogen). The cell cultures were incubated at
37uC atmosphere supplemented with 5% CO2 and subculti-
vated at a ratio of 1:4 twice weekly using TrypLE (Invitrogen).
Hep G2 cells were passed through a 25-gauge needle to
minimize clumping. For experiments, the cells were detached
using Versene-EDTA 1:5,000 (Invitrogen) to minimize
enzymatic cleavage of the GPC3 expressed on the cell surface.
Quantitative Real-Time PCR
Cells were detached using TrypLE and homogenized by
passing through QIAshredder columns (Qiagen, Valencia,
CA). Total ribonucleic acid (RNA) was isolated from Hep
G2 and HLF cells in triplicate using RNeasy (Qiagen), and
30 ng of total RNA for each sample was converted to
complementary deoxyribonucleic acid (cDNA) using the
iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA)
following the manufacturer’s instructions. iQ SYBR
Green Supermix (Bio-Rad) was used for template
amplification with a primer for each of the transcripts
examined. Thermocycling for all targets was carried out in
a solution of 30 mL containing 0.3 mM primers (Integrated
DNA Technologies, San Diego, CA) and 4 pg cDNA from
the reverse transcription reaction under the following
conditions: 15 seconds at 94uC, 30 seconds at 55uC, and
30 seconds at 72uC. The reaction was monitored in real time
using a real-time PCR detection system, CFX96 (BioRad).
Two sets of GPC3 primers with gene product sizes of 250
and 430 base pairs without any gene sequence overlap were
used to confirm the presence of this gene. Primer nucleotide
sequences were as follows: GPC3 250 sense 59-GATAC-
AGCCAAAAGGCAG-39, antisense 59-ATCATTCCATCA-
CCAGAG-39; GPC3 430 sense 59-GCAAGTATGTCTCCC-
TAAGG-39, antisense 59-AGGTCACGTCTTGCTCCTC-39.
GPC3 expression was normalized to expression of the
housekeeping gene GAPDH sense 59-TCGACAGTCAG-
CCGCATCTTCTTT-39, antisense 59-ACCAAATCCGT-
TGATCCGACCTT-39.
Bioconjugation of GPC3 Antibody to Biotin
Purified mouse antihuman monoclonal IgG2A antibody to
GPC3 (aGPC3, 100 mg lyophilized; R&D Systems, Minne-
apolis, MN) was resuspended in 100 mL 0.1 M NaHCO3
(Sigma-Aldrich, St. Louis, MO). 6-((6-((Biotinoyl)amino)
hexanoyl)amino) hexanoic acid, succinimidyl ester, a biotin
moiety with a 14-atom spacer consisting of two aminohex-
anoic acid chains (Biotin-XX, SE, molecular weight (MW)
567.70, 8.4 mg, Invitrogen), was dissolved in 200 mL DMSO
(Sigma-Aldrich) and then diluted with the addition of
800 mL deionized H2O; 1.85 mL of the biotin-XX-DMSO
solution was added to the aGPC3 and incubated at RT
for 15 minutes. A desalting spin column (Zeba 0.5mL, 7,000
MW exclusion limit, ThermoScientific, Rockford, IL)
was equilibrated with 300 mL 0.1 M NaHCO3 washes at
4,000 rpm for 1 minute, and then the biotinylated aGPC3
was passed through the column. Twenty-five microliters of
the purified product was diluted to 1 mL with fluorescence-
Figure 1. Schematic of NP synthesis and illustration of cell targeting.
A, Synthesis of NP-AV-APC. B, Biotinylation of aGPC3. C, Two-step
pretargeting approach of cell labeling.
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activated cell sorting (FACS) buffer (MEM with 2% FBS and
0.04% human IgG; Invitrogen) for cell labeling experiments.
Figure 1B illustrates this conjugation scheme.
Cell Labeling
Hep G2 and HLF cells were detached using Versene,
resuspended in MEM with 10% (v/v) FBS, and counted
with trypan blue exclusion, confirming viability. Cells were
centrifuged at 650 rcf for 7 minutes, and the pellets were
resuspended in FACS buffer at a cell concentration of 4 3
106 cells/mL for flow cytometry, or 1 3 107 cells/mL for MRI
experiments, and incubated on ice for 15 minutes with
periodic gentle mixing. For the NP-AV-APC/aGPC3 group,
purified biotinylated aGPC3 was added to the cells in a
pretargeting step and incubated on ice for 60 minutes with
periodic gentle mixing. Cells were then washed with FACS
buffer and centrifuged at 650 rcf for 7 minutes. Pellets were
resuspended in FACS buffer containing NP-AV-APC and
incubated on ice for 30 minutes with periodic gentle mixing.
For the aGPC3-APC group, 40 mL of APC-labeled aGPC3
(R&D Systems) was added to the cells and incubated on ice
for 30 minutes with periodic gentle mixing. For the control
NP-AV-APC group, untreated cell pellets were resuspended
in FACS buffer containing NP-AV-APC and incubated on
ice for 30 minutes with periodic gentle mixing. All cell group
samples were washed twice with FACS buffer and centrifu-
gation and then resuspended in FACS buffer and fixed with
equal volume of 4% formaldehyde. All experiments were
performed in triplicate. The pretargeting scheme for the NP-
AV-APC/aGPC3 group is illustrated in Figure 1C.
Flow Cytometry
GPC3-targeted labeling of the cells was quantified using flow
cytometry. Fixed cells (4 3 105) were analyzed with a BD
FACSCanto flow cytometer (BD Biosciences, Franklin Lakes,
NJ) equipped with a 633 nm red diode laser for excitation of
Alexa Fluor 647 and APC fluorophores, appropriate
bandpass filters to collect the emission wavelengths, and a
digital instrument using FACSDiva software (BD
Biosciences, San Jose, CA). A minimum of 30,000 cells were
analyzed for each sample, and triplicate samples were
evaluated for each treatment group. Data analysis was
performed on FlowJo version 8.8.6 (Tree Star, Ashland, OR).
In Vitro Fluorescence Microscopy Imaging
Cells from the four treatment groups (cells only, aGPC3-
APC, NP-AV-APC/aGPC3, and NP-AV-APC) were plated
on sterile 24 mm glass cover slides (5 3 105 per slide) and
grown for 24 hours at 37uC in a humidified atmosphere
with 5% CO2. Cells were washed with PBS three times and
fixed in 4% formaldehyde-PBS solution (methanol free;
Polysciences Inc., Warrington, PA) for 30 minutes. The
fixative was then removed, and cells were washed again with
PBS three times. Cell membranes were then labeled with
Alexa Fluor 555 wheat germ agglutinin (Invitrogen)
according to the manufacturer’s instructions. The slides
were then mounted with 49,6-diamidino-2-phenylindole
(DAPI)-containing Prolong Gold antifade solution
(Invitrogen) for cellular nuclei staining and fluorescence
preservation. The slides were examined by fluorescence
microscopy using a Zeiss LSM 510 Meta confocal
fluorescence microscope (Zeiss, Peabody, MA) equipped
with 405 nm diode; 458 nm, 488 nm, 514 nm argon/2; and
633 nm HeNe laser lines for excitation and appropriate
bandpass filters for collection of DAPI, Alexa Fluor 555, and
NIRF (Alexa Fluor 647 and APC) emission signals. In all
fluorescence images, the DAPI signal is depicted in blue, the
Alexa Fluor 555 signal in green, and the NIRF signal in red.
In Vitro MRI
Cell pellets (106 cells) were suspended in 50 mL of 1%
agarose casts. T2 relaxation measurements were performed
on a 4.7 T Bruker magnet (Bruker Medical Systems,
Karlsruhe, Germany) equipped with a Varian Inova
spectrometer (Varian, Inc., Palo Alto, CA). A 5 cm volume
coil and spin-echo imaging sequence were used to acquire
T2-weighted images. Images were acquired using a
repetition time (TR) of 3,000 ms and echo times (TE) of
14.0, 20.0, 40.0, 60.0, 100.0, and 150.0 ms. The spatial
resolution parameters were acquisition matrix of 256 3
128, field of view of 35 3 35 mm, section thickness of
1 mm, and two averages. The T2 map was generated by
ImageJ software (National Institutes of Health [NIH],
Bethesda, MD; ,http://rsb.info.nih.gov/ij/.) based on the
equation SI 5 A ? exp(2TE/T2) + B, where SI is the signal
intensity, TE is the echo time, A is the amplitude, and B is
the offset. The R2 map was generated by taking the
reciprocal of the T2 map.
Results
NP Development and Characterization
The physiochemical properties of NPs, such as size and
surface charge, are important factors that determine the
pharmacokinetics and cellular uptake of NPs.35 In this
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study, fluorophore-labeled streptavidin (AV-APC) immo-
bilized on the surface of iron oxide NPs (NP-AV-APC)
was used to identify and bind to the biotinylated targeting
moiety, GPC3 antibody. Streptavidin (AV), a tetrameric
protein with an isoelectric point value of 5, is well known
for its strong noncovalent binding to biotin with a
dissociation constant of 4 3 10214 M.36 The immobiliza-
tion of streptavidin on the surface of the NP was
confirmed by fluorescence measurements of NP, AV-
APC, and NP-AV-APC after purification (Figure 2A).
Whereas naked NPs show no fluorescent emission, both
AV-APC and NP-AV-APC have a strong emission peak
centered at <665 nm, confirming the presence of AV-APC
on the surface of NP-AV-APC. The zeta potential and
hydrodynamic size of NP-AV-APC were measured. The
NP-AV-APC construct had a zeta potential of 230.4 mV
6 12.4 in deionized water at pH 7.0 (Figure 2B). This
negative charge is a targeting advantage because decreased
surface charge of NPs is reported to reduce nonspecific
uptake by cells (typically negatively charged) and may
increase deep tissue penetration by reduced electrostatic
attraction to extracellular matrices.37 The mean hydro-
dynamic size measured in PBS was 50.4 nm with a
polydispersity index of 0.13 (Figure 2C). NP diameters
between 20 and 150 nm are preferred as diameters less
than 20 nm have been shown to be susceptible to renal
clearance, whereas NPs with diameters less than 150 nm
can extravasate from vasculature into the tumor micro-
environment via enhanced permeability and retention
(EPR) effect and avoid clearance by the RES.38 The
hydrodynamic size corresponds well with the NP core
diameter (<12.5 nm) determined by TEM (Figure 2D).
Differences in the hydrodynamic size and the core size
measured by TEM are attributed to hydration of the PEG
coating and the addition of streptavidin on the polymer
layer. In addition to core diameter, TEM also demonstrates
the relative monodispersity of the NP and a lack of particle
aggregation owing to both the antifouling PEG conjuga-
tion and the electrostatic repulsion between highly
negatively charged NPs.
GPC3 Expression in Hep G2 and HLF Cells
GPC3 was chosen as a molecular target for HCC based on
the accessibility of its cell surface configuration to
antibody-mediated targeting and its differential over-
expression in most HCC cells compared to its absence in
normal adult tissues. Immunohistochemical diagnosis of
HCC using monoclonal GPC3 antibody staining has been
effective in differentiating HCC from benign processes and
other malignancies with 97% specificity.28,29 Microarray
genomic profiling studies have confirmed considerable
upregulation of GPC3 expression in most human HCC
specimens, implicating its role in pathogenesis and
potential as an important biomarker and therapeutic
target.39 The differential levels of GPC3 expression in Hep
G2 (high) and HLF (negligible) cells have previously been
reported; consequently, the Hep G2 and HLF cell lines
have been used as GPC3-positive and GPC3-negative lines,
respectively.30 Quantitative real-time PCR was performed
to confirm this finding in our cells. Two distinct PCR
primer sets for GPC3 resulting in two non–sequence-
overlapping PCR products measuring 250 base pairs and
430 base pairs, respectively, were used to validate the
results. Figure 3 demonstrates the expression level of the
GPC3 gene in both cell lines normalized to the expression
level of the housekeeping gene GAPDH. GPC3 expression
in Hep G2 cells was significantly elevated (320,000-fold
increase) compared to that of the housekeeping gene
GAPDH, whereas GPC3 expression in the HLF cells was
equivalent to that of GAPDH. Both 250 and 430 base-pair
PCR primer sets produced equivalent results (Hep G2 vs
HLF, p , .0001), further validating these results. These
Figure 2. Physicochemical properties of NP-AV-APC. A, Fluorescence
intensity of NP, AV-APC, and NP-AV-APC. B, Zeta potential of NP-
AV-APC at pH 7.0. C, Hydrodynamic size of NP-AV-APC in PBS,
determined by dynamic light scattering. D, TEM image of oleic acid–
coated NPs. Scale bar 5 20 nm.
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findings substantiated the use of these cells for the ensuing
targeting experiments.
Flow Cytometry Experiments
Specific targeting of the GPC3-positive Hep G2 cells using
aGPC3 was demonstrated using flow cytometry. First, Hep
G2 and HLF cells were treated with aGPC3-APC to establish
the feasibility of cell surface targeting using this antibody. As
illustrated in Figure 4, the level of fluorescence, expressed as
the normalized geometric mean, is significantly higher in
the GPC3-positive Hep G2 cells compared to the GPC3-
negative HLF cells (p, .0001), confirming the results of the
PCR experiment. These findings suggest that the GPC3
expressed on the cell surface of Hep G2 cells can clearly be
targeted and labeled by aGPC3, indicating its high affinity
to GPC3. The GPC3-negative HLF cells are not labeled by
aGPC3-APC, denoting this monoclonal antibody’s specifi-
city toward GPC3. In the group designated NP-AV-APC/
aGPC3, the cell surface marker GPC3 was first labeled using
the biotinylated aGPC3 in a pretargeting step; subsequently,
the biotin was targeted using the streptavidin iron oxide NP
construct. This two-step pretargeting approach to enhance
the targeting efficiency of antibody-mediated imaging and
therapy has been previously described.24,25 We used this
two-step pretargeting approach sequentially employing
biotinylated aGPC3 followed by streptavidin-conjugated
NPs to specifically target GPC3-expressing HCC cells (see
Figure 1) and refine the targeting signal. In our preliminary
studies, preconjugated NP-AV-APC/biotin-aGPC3 parti-
cles showed negligible targeting effect for Hep G2 cells
compared to the two-step pretargeting approach. This
finding may be attributed to the NP-AV-APC/biotin-
aGPC3 complexes being subject to significant electrostatic
repulsion owing to the highly negative charged NP-AV-APC
and cell surface interactions, which, in turn, could limit the
interaction of aGPC3 with GPC3 on the cell membrane.
Additionally, steric hindrance between bulky groups such as
NPs (MW 2.8 3 106 based on its 12 nm core diameter) and
streptavidin (MW 6 3 104) near the antibody could also
inhibit antibody–antigen interactions.40 However, biotin–
streptavidin interactions are much stronger than those
between antibody and antigen, which could overcome the
interfering charge repulsion, limiting the opportunity of
interaction between NPs and the cell surface. As shown in
Figure 4, in Hep G2 cells, there was clear demonstration of
GPC3-specific targeting by the NP, as evidenced by a
fourfold increase in the mean fluorescence in the targeted
NP-AV-APC/aGPC3 group compared to the nontargeted
NP-AV-APC control group (p , .0001) using the
pretargeted approach. No difference in mean fluorescence
was observed between the targeted NP-AV-APC/aGPC3
group and the NP-AV-APC control group for the GPC3-
negative HLF cells.
Figure 3. Relative GPC3 expression in Hep G2 and HLF cells
determined by real-time PCR for two non–sequence-overlapping PCR
products measuring 250 and 430 base pairs.
Figure 4. Normalized geometric mean fluorescence of Hep G2 and
HLF cells treated with either aGPC3-APC, NP-AV-APC/aGPC3, or
NP-AV-APC, determined by flow cytometry.
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Confocal Fluorescence Imaging
In this study, NIR fluorophore was immobilized onto NPs
as a dual-modality imaging agent, which could endow
enhanced image resolution for clinical application.
Targeted cellular labeling using aGPC3 and cellular
localization of either aGPC3-APC or NP-AV-APC/
aGPC3 was visualized by confocal fluorescence micro-
scopy. Fluorescence images of Hep G2 (Figure 5A) and
HLF (Figure 5B) cells further confirmed the results of the
flow cytometry studies. The GPC3-positive Hep G2 cells
treated with aGPC3-APC demonstrated cell membrane
labeling, whereas the GPC3-negative HLF cells did not.
Hep G2 cells treated with biotinylated aGPC3 followed by
NP-AV-APC demonstrated cell membrane labeling with
fluorophore. Hep G2 cells treated with the control NP-AV-
APC demonstrated negligible fluorescence, indicating that
the NP-AV-APC itself exhibited low nonspecific uptake or
binding by these cells. The HLF cells were not labeled by
either the aGPC3-APC or the biotinylated aGPC3 bound
by NP-AV-APC particles. In summary, the fluorophore
labeling seen on imaging by either the APC-labeled aGPC3
or the biotinylated aGPC3 bound to NP-AV-APC was
specific to the GPC3-expressing Hep G2 cells.
In Vitro MRI
To ensure that the NP-AV-APC construct retains sufficient
magnetism after cell surface labeling and to test the
potential use of these particles as a GPC3-specific MRI
contrast agent for HCC, the magnetic properties of the
NP-AV-APC were studied. R2 relaxation was evaluated at
4.7 T by acquiring phantom MRIs of agarose with 1 3 106
cells per each of the four treatment groups for both Hep
G2 and HLF cells. The colorized R2 maps in Figure 6A and
quantitative R2 calculations in Figure 6B demonstrate
significantly increased relaxivity measurements for Hep G2
cells treated with biotinylated aGPC3 followed by NP-AV-
APC particles compared to other conditions and to HLF
cells. For Hep G2 cells in the NP-AV-APC/aGPC3 group,
there was a threefold increase in R2 values over untreated
cells and a significant increase over cells treated with
nontargeted NP-AV-APC. HLF cells in the NP-AV-APC/
aGPC3 group demonstrated an increase in R2 value over
those in the cells-only group. However, the uptake was not
significantly different from the R2 value in the nontargeted
NP-AV-APC group. These results suggest that a greater
number of magnetic NPs bound to the cell surface of Hep
G2 cells in the NP-AV-APC/aGPC3 group compared to
the nontargeted NP-AV-APC group. Additionally, a
greater number of magnetic NPs bound to the Hep G2
cells in the NP-AV-APC/aGPC3 group compared to the
HLF groups treated with NP-AV-APC/aGPC3 and NP-
AV-APC, confirming GPC3-specific targeting and demon-
strating the potential of this NP construct as an effective
MRI contrast agent.
Discussion
This study is the first proof-of-concept demonstration that
GPC3, a surface receptor overexpressed in most HCCs, can
be employed as a novel molecular target to specifically
identify HCC cells using a multifunctional NP. Various
nanoscale constructs and targets have been evaluated for
Figure 5. Confocal fluorescence ima-
ging of GPC3 targeting for (A) Hep
G2 cells and (B) HLF cells either
untreated or treated with aGPC3-
APC, NP-AV-APC/aGPC3, or NP-
AV-APC.
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specific targeting of HCC, with limited efficacy. This novel
NP construct has a number of advantages in its design and
application. First, the target ligand GPC3 is a proteoglycan
expressed on the cell surface of most HCCs, potentially
making it widely applicable to most HCC patients. In
contrast, normal adult human cells and tissues, and even
dysplastic nodules found in cirrhotic livers that often
account for indeterminate lesions encountered on conven-
tional CT or MRI, lack GPC3 expression, making GPC3 a
potentially powerful tool to discriminate between these
benign entities and HCC.41 Our study clearly illustrates the
ability of aGPC3 to target GPC3-expressing HCC cells with
high specificity. Second, the characteristics of the NP
construct are optimal for targeted delivery to the cells of
interest and an ideal target-specific imaging contrast agent
in terms of particle size and zeta potential. The hydro-
dynamic size of 50 nm is large enough so that it will not be
quickly filtered out through the glomeruli but small enough
that it can evade the RES clearance by the EPR effect. A
negative zeta potential also minimizes unwanted nonspe-
cific binding and uptake by surrounding tissues and allows
for deeper tissue penetration to the target.37 The NP
construct also has the unique advantage of dual-modality
imaging: targeted MRI, which can be used for pretreatment
staging or planning, and targeted NIRF imaging, which can
be used in the operating theater to ensure adequate surgical
margins during tumor resection. It also offers potential use
as a nanocarrier for HCC-targeted therapeutics, delivering
drugs and other payloads. For all of these reasons, this
GPC3-targeted NP system may potentially improve the
diagnosis of indeterminate liver lesions, which, in turn, will
enhance the accuracy of staging and surgical risk stratifica-
tion of the HCC patient.
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